Qtrex Quantum Ltd. · NASDAQ:QTEX

Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (October 2021)

27 slides from Qtrex Quantum's investor presentation, Oct 12, 2021

Slide 2: Forward looking Statements
Forward looking - Statements 2 Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved This presentation of Inspira TM Technologies Oxy B . H . N . Ltd . (the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform A
Slide 3: Mechanical Ventilation Has Significant Downsides
1. Am J Respir Crit Care Med Vol. 196, P3 - 4, 2017. ATS Patient Education Series © 2017 American Thoracic Society 2. Diling Wu et al. Frontiers in pharmacology MINI REVIEW published: 09 May 2019. doi: 10.3389/fphar.2019.00482 3. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hos
Slide 4: Inspira Technologies early extracorporeal blood oxygenation system
Inspira TM Technologies is developing a potentially minimally invasive, cost - effective early extracorporeal blood oxygenation system that utilizes a proprietary hemo - protective Flow technology to rebalance oxygen saturation levels in one minute*, while the patient is awake and maintaining sponta
Slide 5: Vision
Vision Redefining Artificial Respiration to impact millions of lives 5 Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved 5 Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved
Slide 6: Investment Highlights
Investment Highlights Targeted medical Device companies 1. “Respiratory Care Devices Market by Product”. Report by “Research and Market”, June 2020. ID: 5129035 2. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory
Slide 7: Our mission: new standard of care for acute respiratory patients
Our mission is to become the new standard of care, for acute respiratory patients, to be applied in awake and breathing patients. Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved 7
Slide 8: The ART device Early Extracorporeal Respiratory Support
The ART Ρ device Early Extracorporeal Respiratory Support 8 Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved The product is currently in a developmental stage and has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administra
Slide 9: The ART Device: Taking the load off the lungs
THE ART TM DEVICE Taking the load off the lungs INSERT Dual lumen cannula inserted into the jugular vein WITHDRAW Utilizing hemo - protective flow technology, the blood is treated with a minimum drop in blood pressure & a low shear force, protecting the red blood cells Copyright © 2018 - 2021 Inspir
Slide 10: The ART device components
Oxygenator Initiation System Pump THE ART TM T h e A R T d e vic e i s c om pri s e d o f a per m ane n t mo dul e an d a di s p os abl e r e s pi r a t o r y s upp o r t unit. T h e c om pa n y ’ s s t r a t e g i c bu s ine s s mo de l i s de s i g ne d t o enabl e t h e e x t en s i o n o f acu t
Slide 11: ART Device Primary Components
Dual Lumen Cannula & Adjustable Dual Lumen Component: L o w i m pac t r adiog r ap h y - f r e e dua l lu m e n c annula , w i t h sm al l dia m e t e r (18Fr ) an d a n t i - ai r - e m b o l i s m m echani s m t h a t e xpec t e d t o d r a w blood at a rate of 1 - 1.5L per minute* Initiation Syst
Slide 12: ART's Innovative Features
ART ’ s Innovative Features Hemo - protective flow technology aimed to reduce the risks of hemolysis & thrombosis Single insertion point of dual - lumen cannula aimed at lowering the risk of multiple infections & bleeding Proprietary plug - and - play disposable unit expected to reduce need for ICU
Slide 13: ART's Proprietary Hemo-Protective Flow Technology
A R T ’ s P r oprie t a r y H e m o - P r o t e c t i v e Flow Technology Features Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved 13 ~ 200cc of blood are being enriched at any given point, providing the patient a saturation boost in 1 minute* P r e s e n t in g inn
Slide 14: ART's Respiratory Support System Potential Benefits
ART's Respiratory Support System Potential Benefits • Reduced costs associated with MV c om p li ca tions • Increased patient throughput • Better respiratory care in ward setting • Reduction of patient load in ICU • Reduced staffing - No need for perfusionists • No need for surgical access team The
Slide 15: ART Offers Two Intervention Modalities
ART TM Offers Two Intervention Modalities Avoid VALI, Awake & breathing patients with deteriorating respiratory failure WHO WHERE • Avoid intubation, coma and MV • VIDD and VAP ICU General Medical Unit WH A T V A L U E MV = Mechanical Ventilation VALI = Ventilator - associated lung injury VIDD = Ven
Slide 16: Study Results
Study Results Substantial ongoing positive changes in the blood oxygenation levels Reference for normal levels - Julia Hooley, MSN, RN. American Nurse Today. Volume 10, Number 1. January 2015 Throughout 2019 - 2020, 25 animal studies were performed in 2 swine models by the veterinary team at LAHAV C
Slide 17: Intended Patient Population and Lines of Therapy
Intended Patient Population and Lines of Therapy Adult COPD patients (Chronic Obstructive Pulmonary Disease) Patient Population Acute hypoxemic failure adult patients T R E A T M E N T E S C E L A T I O N RESPIRATORY DETERIORATIO • Nasal mask • F ace mask • Nasal pl u gs • BiPAP • CPAP Non - Invasiv
Slide 18: $20Bn Total Addressable Market for the ART
$20Bn Total Addressable Market for the ART TM 20 million globally per year¹ 1,250$ per treatment/disposable unit (estimated target price) $20 Bn T o t al Ma r k e t* *80% of 20 million¹ patients annually¹ (treated today by MV) at a direct treatment cost of $1,250 for ART disposables unit (cost per p
Slide 19: Market Penetration and Gaining Market Share
Market Penetration and Gaining Market Share We have developed a flexible business model to drive global deployment PRICING MODEL ART device distributed as an OPEX when bundled with 15 disposable respiratory support units X 15 Novel technology ART device Disposable respiratory support units + Healthc
Slide 20: Reimbursement Strategy
Reimbursement Strategy Inspira plans to utilize existing CPT Codes using a “New Approach” to an existing procedure E xp ec t e d t o e li m in a t e complications a ssoc i at e d w it h M V A i m e d t o r e du c e l e n g t h o f s ta y & r e - ad m i ss i o n s D es i gn e d t o r e du ce d c o s
Slide 21: Go-to-Market Strategy
Go - to - Market Strategy Establishing multiple recurring revenue streams across medical sectors & markets PURSUING WORLD - WIDE R E G U L A T O R Y AP P R O V A L S Uni t ed S t a t es Europe Asia S outh Ameri c a Africa Middle East COLLABORATING WITH STRATEGIC MEDICAL CENTERS & PROFESSIONAL ASSOCI
Slide 22: Regulatory Submission (Multi-Step approach)
Regulatory Submission (Multi - Step approach) Q 4 - 2021 Components ART ART TM 510(k) Support De Novo* ECLS 510(k) To - date the ART500 has not been tested on humans and is subject to the regulator’s requirement. *Will require a new 510(k) marketing clearance or, depending on the modification, a de
Slide 23: Targeting Major Milestones 2021-2023
Targeting Major Milestones 2021 - 2023 H1 - 2022 Strategi c A g ree m ent Distribution Agreement Component Deployment FDA Filing Component 510(k) COMPONENT H2 - 2022 FDA 510(k) Filings - ART support ECLS - Components Distri b u ti o n A g ree m ent Medical Collaboration Regulatory Filings Dist r i b
Slide 24: Leadership
Leadership Urologic surgeon, inventor, entrepreneur & venture capital investor. Vast experience in leading high growth, publicly traded medical companies. Co - founded Vidamed Inc., acquired by Medtronic Inc. (NYSE: MDT). Co - founded Medinol, partnered with Boston Scientific (NYSE: BSX). Copyright
Slide 25: Scientific Advisory Board
Scientific Advisory Board Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved 25 Respiratory physician & specialist in respiratory disease. Professor of Respiratory Medicine at University of Notre Dame & University of WA. Chairman of Research at UND, Director of the WA
Slide 26: Scientific Advisory Board - cont.
Scientific Advisory Board - cont. Dr. Dekel Stavi, MD I n tens i vist Ad visor Has considerable experience in leadership and Extracorporeal Life Support programs, cardiology aspects of Intensive Care Unit (“ICU”) patients and treating hemato - oncology patients in ICUs. Prior to joining the interdep

Inspira Technologies OXY B.H.N. — Investor Presentation (October 2021) on 6ix

Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (October 2021)

Slide 1: Revolutionizing Acute Respiratory Care

Slide 2: Forward looking Statements

Slide 3: Mechanical Ventilation Has Significant Downsides

Slide 4: Inspira Technologies early extracorporeal blood oxygenation system

Slide 5: Vision

Slide 6: Investment Highlights

Slide 7: Our mission: new standard of care for acute respiratory patients

Slide 8: The ART device Early Extracorporeal Respiratory Support

Slide 9: The ART Device: Taking the load off the lungs

Slide 10: The ART device components

Slide 11: ART Device Primary Components

Slide 12: ART's Innovative Features

Slide 13: ART's Proprietary Hemo-Protective Flow Technology

Slide 14: ART's Respiratory Support System Potential Benefits

Slide 15: ART Offers Two Intervention Modalities

Slide 16: Study Results

Slide 17: Intended Patient Population and Lines of Therapy

Slide 18: $20Bn Total Addressable Market for the ART

Slide 19: Market Penetration and Gaining Market Share

Slide 20: Reimbursement Strategy

Slide 21: Go-to-Market Strategy

Slide 22: Regulatory Submission (Multi-Step approach)

Slide 23: Targeting Major Milestones 2021-2023

Slide 24: Leadership

Slide 25: Scientific Advisory Board

Slide 26: Scientific Advisory Board - cont.

Slide 27: Thank You